![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Shanghai Bangyao Biotechnology Co., Ltd. - BioRay Laboratories
Main focus: Gene editing of haematopoietic stem cells and next generation CAR-T cells
Company stage: Clinical
Diseases: Beta-thalassemia, alpha-thalassemia, multiple haematological and solid tumours
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Shanghai, China
Website: https://www.bioraylab.com/
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_BRL_medicine_5e98381034_0e4b3f11dd.png)
Bioray Laboratories is a Shanghai-based company focusing on the development of haematopoietic stem cell (HSCs)-based medicines as well as next generation CAR-T cell-based therapies. The company uses CRISPR to knock out various targets within the genomes of HSCs and CAR-T cells. Currently, the company is conducting multiple clinical trials in which CRISPR-Cas9 is being used for the treatment of beta-thalassemia and B-cell lymphomas using CAR-T.
Tags
Shanghai Bangyao Biotechnology Co., Ltd. - BioRay Laboratories